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Rhinology
Prognostic value of the Sinonasal Outcome Test 22 
(SNOT-22) in chronic rhinosinusitis
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1 Department of Otorhinolaryngology, University of Insubria and ASST Sette Laghi, Varese, Italy; 2 Department of Biotechnology 
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SUMMARY
Previous studies have highlighted that baseline Sinonasal Outcome Test 22 (SNOT-22) score 
affects surgical outcomes in chronic rhinosinusitis (CRS) and suggested that a SNOT-22-based 
approach might ameliorate patients’ understanding of expectations after treatment. Our study 
aimed at verifying this hypothesis in an Italian CRS population. In 457 CRS patients treated 
with endoscopic sinus surgery after failure of maximal medical therapy, the percentage of 
achieving a minimal clinically important difference (MCID) and the percentage of relative 
improvement after surgery were calculated. Moreover, the impact of several factors on preop-
erative and postoperative SNOT-22 score was investigated. Symptom improvement occurred in 
the majority of patients and was directly proportional to baseline SNOT-22. 79,7% of patients 
achieved the MCID and the percentage of relative improvement was 50,1%. Psychological 
and social-functioning implications significantly affected SNOT-22 scores. Multiple regression 
analysis showed that history of previous surgery, asthma, preoperative endoscopic and SNOT-
22 scores predicted the postoperative SNOT-22 score (R2 = 0,298). Submitting CRS patients to 
SNOT-22 prior to surgical treatments might help to inform about probable outcomes, although 
it is strongly influenced by individual perception. Further studies are needed to identify an ef-
fective set of subjective and objective parameters for evaluation of outcomes.
KEY WORDS: Sinonasal Outcome Test-22 (SNOT-22), chronic rhinosinusitis, endoscopic 
sinus surgery, outcome prediction, quality of life
RIASSUNTO
Studi in letteratura hanno evidenziato che il punteggio basale del Sinonasal Outcome Test 22 
(SNOT-22) influenza l’outcome chirurgico nella rinosinusite cronica (CRS) ed hanno suggerito 
che un approccio SNOT-22-mediato potrebbe migliorare la comprensione delle aspettative dei 
pazienti dopo il trattamento. Il presente studio mirava a verificare questa ipotesi in una popola-
zione italiana di CRS. In 457 pazienti con CRS, trattati con chirurgia endoscopica endonasale 
dopo fallimento della terapia medica massimale, sono stati calcolati la percentuale di raggiun-
gimento della differenza minima clinicamente rilevabile (MCID) e la percentuale di migliora-
mento relativo dopo l’intervento chirurgico. Inoltre, è stato studiato l’impatto di diversi fattori 
sul punteggio dello SNOT-22 preoperatorio e postoperatorio. Il miglioramento dei sintomi si 
è verificato nella maggior parte dei pazienti ed era direttamente proporzionale alla SNOT-22 
basale. Il 79,7% dei pazienti ha raggiunto l’MCID e la percentuale di miglioramento relativo 
è stata del 50,1%. Le implicazioni psicologiche e sociali hanno influenzato significativamente 
i punteggi dello SNOT-22. Un’analisi di regressione multipla ha mostrato che la storia di pre-
cedenti interventi chirurgici, asma, score endoscopico preoperatorio e SNOT-22 basale hanno 
statisticamente predetto il punteggio dello SNOT-22 postoperatorio (R2 = 0,229). Sottoporre i 
pazienti con CRS a SNOT-22 prima dei trattamenti chirurgici potrebbe quindi aiutare ad infor-
marli sui probabili esiti, sebbene sia fortemente influenzato dalla percezione individuale. Sono 
necessari ulteriori studi per identificare un set efficace di parametri soggettivi e oggettivi per la 
valutazione dei risultati.
PAROLE CHIAVE: Sinonasal Outcome Test-22 (SNOT-22), rinosinusite cronica, chirurgia 
endoscopica nasosinusale, previsione dell’outcome, qualità della vita 
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Introduction
Since the advent of nasal endoscopy, the evaluation 
of treatment outcomes in patients affected by chronic 
rhinosinusitis (CRS) has been a matter of debate. The 
pioneers of endoscopic sinus surgery (ESS) demonstrated 
surgical success rates of around 90-95% 1. However, these 
results are far from the actual rates reported in literature. 
This is easily explained in two ways. As ESS was introduced 
recently in the 1980s and it was not in widespread practice, 
there was a lack of long-term follow-up studies that 
described the actual surgical effects 2. Moreover, evaluation 
method of outcomes was based on qualitative scales, often 
estimating changes only on one or a few items of the 
CRS symptoms criteria, lacking a global assessment of 
improvement  3,4. Finally, and this is partly also a current 
issue, the cohorts of patients were inhomogeneous, including 
cases of acute rhinosinusitis, massive nasal polyposis, or 
recurrent sinusitis after external procedures  5. The 1990s 
witnessed the clinical application of the biopsychosocial 
model 6. This theory supported that, in order to understand 
and respond adequately to patient suffering, clinicians 
should consider the biological, psychological and social 
dimensions of illness simultaneously. In practice, this was 
a way of considering the patient’s subjective experience 
as an essential contributor to accurate diagnosis, health 
outcomes and humane care. In accordance with this 
philosophy, a “quality of life revolution” was observed 
in different areas of medicine 7 and several quality of life 
(QoL) questionnaires have been developed to quantify 
the individual and societal burden of chronic diseases. 
This paradigm shift also occurred for CRS. Since then, 
rhinologists have used several specific symptom-based 
scores to evaluate treatment outcomes in CRS patients, 
such as the Sinonasal Outcome Test 22 (SNOT-22)  8. 
Applying these tools, it emerged that around 20-30% of 
CRS patients do not experience significant improvement 
after surgery, although the impact of ESS on QoL is 
generally reported as positive  9. Moreover, other studies 
have quantified the 5-year risk of revision surgery to be 
10-20%, while the presence of certain comorbidities, such 
as asthma and aspirin sensitivity, along with other factors 
like high baseline CT stage or incomplete sinus dissection, 
have been associated with elevated revision rates of 25-
40%. However, despite the presence of known risk factors 
for revision surgery, evidence for several of these clinical 
characteristics has failed to reliably predict ESS outcomes 9. 
Contrarily, it seems from previous regression studies that 
baseline SNOT-22 is one of the most important factors 
affecting the outcome  10 and several studies suggested its 
prognostic role in terms of achievement of improvement 
and risk of revision surgery 11. In light of these observations, 
the presented study aimed at verifying in an Italian CRS 
population whether SNOT-22 could assist physicians in 
predicting surgical outcomes, improving shared decision-
making process and ameliorating patients’ understanding 
of their QoL expectations after treatment. The primary 
outcomes included measurement of the percentage of 
patients receiving a minimal clinically important difference 
(MCID) and the percentage of relative improvement (RI) 
after surgical treatment.
Materials and methods
This prospective study was conducted according to the 
declaration of Helsinki and was previously approved by the 
Institutional Review Board of the hospital (n. 109/2016).
Clinical data were obtained from a population of 457 
patients affected by CRS operated in the same tertiary care 
centre in the period 2015-2018. 
Enrolled patients were adult subjects affected by bilateral 
CRS undergoing ESS as a primary procedure after failure 
of maximal medical therapy 12. All study participants had 
completed previous medical therapy including, but not 
limited to, at least two courses of topical steroid (60 days 
each). Oral steroid or culture-directed antibiotics were 
added when necessary (at least one course of 15 and 
10 days respectively). However, medical therapy was not 
suspended until surgery.
Exclusion criteria were previous trauma, congenital facial 
malformations, systemic autoimmune diseases, cystic 
fibrosis, ciliary dyskinesia, head and neck malignancies or 
history of previous radiotherapy, any other nasal surgery 
performed concomitantly.
All surgical procedures were performed by the same 4 
surgeons with more than 10 years of experience in ESS. 
Postoperative medical therapy consisted in nasal irrigation 
with saline solution and intranasal corticosteroid  12, 
delivered with a high-volume squeeze bottle device  13. A 
perioperative short-term of oral corticosteroid was also 
administered. Non-standardised oral steroid or culture-
directed antibiotic therapy were added in cases of recurrent 
infection or uncontrolled symptoms. Patients were followed 
at 15 days, 1, 3, 6 and 12 months after surgery. 
Each patient was evaluated about 15 days before surgery 
and during follow-up visits using a set of objective and 
subjective (self-assessed) measurements. Data obtained in 
the preoperative assessment and during the last follow-up 
visit (12 months) were collected for analysis. 
Concerning the objective evaluation, the Lund-Kennedy 
(LK)  14 and the Lund-Mackay (LM)  15 scales were used. 
The evaluation between preoperative and postoperative LM 
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scores was not possible, because CT scan is not routinely 
performed after surgery unless required for particular 
clinical conditions.
For subjective evaluation, the Italian version of the Sino-
Nasal Outcome Test-22 (I-SNOT-22) 16 was used. It is the 
most frequently employed in clinical practice because it is 
simple, intuitive and takes only a few minutes to complete 17. 
It represents a questionnaire structurally composed of 22 
CRS-related items scored from 0 to 5 (total score range 
0-110, higher scores represent worse symptoms), which 
evaluates the severity of complaints that patients have been 
experiencing over the past weeks due to CRS 18. SNOT-22 
items can be divided into 2 categories: questions about 
physical symptoms (items 1-12) which cover rhinologic 
as well as ear and facial symptoms, and questions about 
health and QOL (items 13-22) which cover sleep function 
and psychological issues 19. 
Similar to Rudmik  20, the cohort of patients was divided 
into 10 groups according to baseline SNOT-22 score. These 
groups were based on 10-point increments of the SNOT-22 
score (patients who scored less than 10 were excluded since 
they had no chance to receive an MCID). The percentage 
of patients reaching at least an MCID, which in SNOT-22 
is defined as a reduction of around 9 points after ESS  21, 
was estimated. The percentage of RI for each preoperative 
SNOT-22 group was then calculated with the formula 
[(mean postoperative SNOT-22 score - mean preoperative 
SNOT-22 score)/mean preoperative SNOT-22 score] x 
100 20.
Statistical analysis 
Results are given as arithmetic mean ± standard deviation. 
The Kolmogorov Smirnoff test was used to test the 
normality of distribution. Parametric tests were used to 
evaluate differences between groups. In particular, ANOVA 
test with Tukey post-hoc test and Chi-square test were used 
when appropriate to compare groups. A multiple regression 
analysis was run to predict the SNOT-22 postoperative 
score from age, sex, smoking habit, asthma, allergy, aspirin 
intolerance, LK score, LM score, history of previous surgery 
for CRS and preoperative SNOT-22 score. A significance 
level of 0.05 for all testing was used. Statistical analyses 
were performed using the SPSS 25.0 package.
Results
A total of 457 CRS patients were consecutively enrolled. 
Among these, 34 patients were lost to follow-up. The 
remaining 423 patients attended the scheduled follow-
up visits for 12 months and were considered eligible for 
analysis. The mean age of the cohort was 47.4  ±  13.5 
years (range  18-86 years). 112 patients were asthmatic 
(26.5%) and 156  patients were allergic to common 
inhalants (36.9%), while 31 patients complained aspirin 
intolerance (7.3%). 225  patients were affected by CRS 
with nasal polyps (CRSwNP) (53.2%), while the remaining 
198 (46.8%) were affected by CRS without nasal polyps 
(CRSsNP). 
The mean preoperative SNOT-22 score was 48.9  ±  20.8 
(range 13-106), and the mean preoperative SNOT 1-12 
score was 30.8  ±  10.3 (range 9-56). The preoperative 
SNOT 1-12 score accounted for the total SNOT-22 for 
67.4% (percentage of the SNOT-22 related to rhinologic 
symptoms). The mean preoperative LK score was 5.6 ± 2.8 
(range 0-12), while the mean preoperative LM score 
was 11.5  ±  6.6 (range 0-24). The mean postoperative 
SNOT-22 score was 22.9 ± 17.9 (range 1-75), and the mean 
postoperative SNOT 1-12 score was 14.3 ± 9.5 (range 1-41). 
The postoperative SNOT 1-12 score accounted for the total 
SNOT-22 for 70.7%. The mean postoperative LK score was 
1.7 ± 2.1 (range 0-10). These differences were significant 
at Student’s t test (p = 0.001 for SNOT-22 score; p = 0.001 
for SNOT 1-12 score; p  =  0.001 for the percentage of 
SNOT-22 related to rhinologic symptoms, and p = 0.001 
for LK score). 
Based on baseline SNOT-22 score, 10 different groups of 
patients were defined. The sample sizes for each preoperative 
SNOT-22 group appeared to follow a normal distribution 
(p = 0.132 at Kolmogorov-Smirnoff test), with the largest 
groups composed of patients with baseline SNOT-22 scores 
between 20-69 (Fig. 1). Clinical characteristics, as well as 
preoperative subjective and objective scores, are depicted 
in Table I. 
Postoperative SNOT-22 score was significantly improved 
in each of the 10 groups at paired Student’s t test (p = 0.001 
for all comparisons). 79.7% of the total cohort achieved 
a MCID improvement after ESS. Among the patients 
who achieved a MCID, the percentage of RI was 62.7%. 
When considering the total cohort (including also those 
who did not achieved a MCID) the percentage of RI was 
50.1%. The MCID and the percentage of RI obtained from 
each of the 10 groups, as well as pre- and postoperative 
SNOT-22 scores are reported in Table II. A clear distinction 
of behaviour was observed between patients with baseline 
SNOT-22 score greater or less than 30. In particular, the 
mean percentage of achieving a MCID in groups 3-10 is 
91.6% with an average 56.8% of RI. Contrarily, the mean 
percentage of achieving a MCID in groups 1-2 is 44.2% 
with an average of 38.9% of RI.
Significant differences in the number of patients achieving 
the MCID were demonstrated by the chi-square test 
(p  =  0.001). In detail, patients in groups 1-2 achieved a 
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MCID with a significant less frequency than those in the 
other groups. Furthermore, the percentage of RI among the 
10 groups was also significantly different at ANOVA test 
(p = 0.002) and patients in group 2 scored significantly lower 
than those in group 6, 8 and 10 (p = 0.013, p = 0.022 and 
p = 0.039, respectively, Tukey post-hoc test). Interestingly, 
the percentage of the SNOT-22 score related to nasal 
symptoms was significantly different among the 10 groups 
in both the pre- and post-treatment conditions (p = 0.001 
and p = 0.001, respectively, ANOVA test). In particular, at 
baseline, the SNOT 1-12 score accounted for 88.5% of the 
SNOT-22 total score in group 1, while it accounted for the 
51.9% in group 10. These differences were significant with 
Tukey’s post-hoc test. In the post-treatment assessment, the 
SNOT 1-12 score ranged from 88.0% of the SNOT-22 total 
score in group 1 to 54.5% in group 9. These differences 
were significant by Tukey’s post-hoc test.
Each of the 10 groups was further divided into two 
subgroups according to the presence of polyps. The results 
of SNOT-22 scores obtained before and after the surgery, 
Figure 1. Distribution of the study population according to baseline SNOT-22 score.
Table I. Pre-treatment clinical features of the study population classified in 10 groups based on baseline SNOT-22 score. 
Group 1
(10-19)
Group 2
(20-29)
Group 3
(30-39)
Group 4 
(40-49)
Group 5 
(50-59)
Group 6 
(60-69)
Group 7 
(70-79)
Group 8 
(80-89)
Group 9 
(90-99)
Group 10
(100-110)
N (%) 24 (5.7) 60 (14.2) 68 (16.1) 86 (20.3) 56 (13.2) 51 (12.1) 44 (10.4) 18 (4.3) 10 (2.4) 6 (1.4)
Age 48.3 ± 16.6 
(18-73)
49.1 ± 15.4 
(18-71)
47.7 ± 16.5 
(18-80)
50.4 ± 12.3 
(21-86)
47.1 ± 12.7 
(22-77)
46.2 ± 11.1 
(27-67)
43.6 ± 10.9 
(24-65)
42.1 ± 11.1 
(24-61)
42.2 ± 6.6 
(34-53)
47.3 ± 9.1 
(41-59)
Sex (M:F) 16:8 52:26 44:24 54:32 28:28 33:18 22:22 8:10 2:8 2:4
Asthma, 
n (%)
10 
(41.7%)
14 
(23.3%)
18 
(26.5%)
18 
(20.9%)
18 
(32.1%)
8 
(15.7%)
14 
(31.8%)
4 
(22.2%)
8 
(80%)
0 
(0%)
Allergy, 
n (%)
8 
(33.3%)
25 
(41.7%)
22 
(32.6%)
18 
(20.9%)
26
 (46.4%)
23 
(45.1%)
20 
(45.5%)
10 
(55.6%)
4 
(40%)
0 
(0%)
Aspirin 
intolerance, 
n (%)
2 
(8.3%)
4 
(6.7%)
2 
(2.9%)
8 
(9.3%)
6 
(10.7%)
5 
(9.8%)
0 
(0%)
4 
(22.2%)
0 
(0%)
0 
(0%)
CRSwNP, 
n (%)
14 
(58.3%)
33 
(55%)
36 
(52.9%)
36 
(41.9%)
30 
(53.6%)
26 
(50.9%)
26 
(59.1%)
12 
(66.7%)
6 
(60%)
6 
(100%)
LK score 4.9 4.9 6 6.1 5.8 5.4 5.3 5.4 5.6 5.7
LM score 11.3 10.6 11.5 13.6 11.6 11.3 7.8 12.4 14.6 10.3
M: male; F: female; CRSwNP:chronic rhinosinusitis with nasal polyps; LK: Lund-Kennedy; LM: Lund-Mackay.
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as well as the probability of achieving a MCID and the 
percentage of RI are reported in Table III and Table IV. No 
differences between CRSwNP and CRSsNP patients in the 
postoperative SNOT-22 score (p = 0.177), the percentage of 
the SNOT-22 score related to rhinologic symptoms in the 
pre- (p = 0.366) and post-treatment (p = 0.300) conditions, 
and the percentage of the RI (p = 0.162) were demonstrated 
by Student’s t test. Moreover, no difference in the probability 
of achieving a MCID was demonstrated at chi-square test 
(p = 0.215). On the contrary, a significant difference in the 
baseline SNOT-22 score was found with the Student’s t 
test (p = 0.010). In particular, patients affected by CRSsNP 
scored significantly better than those affected by CRSwNP. 
A multiple regression analysis was run to predict the 
postoperative SNOT-22 score from gender, age, smoke, 
asthma, LK, LM, previous surgery, allergy, aspirin 
intolerance and preoperative SNOT-22 score. Some of 
these variables predicted the postoperative SNOT-22 score, 
F(9, 423)  =  6.423, p  =  0.001, R2  =  0.298. A history of 
previous surgery for CRS was the most important predictor 
(B  =  6.277, p  =  0.009). Other factors predicting ESS 
outcomes included the presence of asthma (B  =  5.286, 
p = 0.045), preoperative LK score (B = 0.937, p = 0.040) 
and preoperative SNOT-22 score (B = 0.326, p = 0.001). 
Discussion
Chronic rhinosinusitis affects a large portion of the world 
population leading to significant impairment of QoL  12. 
Current studies report that about half of CRS patients remain 
symptomatic despite first-line pharmacological therapy 22. 
Consequently, patients and physicians have to make a 
decision as whether to continue with medical therapy alone 
or undergo ESS followed by pharmacological therapy. On 
Table II. Probability of patients with CRS achieving MCID after ESS based on preoperative SNOT-22 score group.
Preop.
SNOT-22 score
%
SNOT 1-12 over 
preop. SNOT-22
Postop. 
SNOT-22 score
%
SNOT 1-12 over 
postop. SNOT-22
Probability 
of achieving MCID 
(%)
RI 
(%)
Group 1
(10-19) 
n = 24
16 ± 2.2 88.5% 8.7 ± 3.8 88.0% 33.3%
(n = 8)
- 44%
Group 2
(20-29)
n = 60
24.8 ± 2.9 82.1% 16.3 ± 12.2 75.6% 55%
(n = 33)
- 33.8%
Group 3 
(30-39) 
n = 68
34 ± 2.7 76.4% 17.5 ± 13.6 79.9% 82.4%
(n = 56)
- 49%
Group 4 
(40-49) 
n = 86
44.5 ± 3.1 67.2% 22.9 ± 16.8 66.8% 86.1%
(n = 76)
- 48.9%
Group 5 
(50-59) 
n = 56
54.2 ± 2.8 58.9% 25.9 ± 15.8 63.8% 85.7%
(n = 48)
- 52%
Group 6 
(60-69) 
n = 51
65.4 ± 3.2 57.5% 23.1 ± 19.2 69.9% 92.1%
(n = 47)
- 64.6%
Group 7 
(70-79) 
n = 44
73.9 ± 2.8 55.8% 35.6 ± 21.9 62.4% 86.3%
(n = 38)
- 51.6%
Group 7 
(80-89) 
n = 18
82 ± 2 53.7% 32.8 ± 21.4 68.6% 100%
(n = 18)
- 60.2%
Group 9 
(90-99) 
n = 10
94.6 ± 3.6 53.5% 43.8 ± 21.6 54.5% 100%
(n = 10)
- 53.8%
Group 10 
(100-110) 
n = 6
104 ± 2.4 51.9% 26.7 ± 14.5 69.4% 100%
(n = 6)
- 74.3%
Total 
n = 423
48.9 ± 20.8 67.4% 22.9 ± 17.9 70.7% 79.7%
(n = 338)
- 50.1%
MCID: minimal clinical important difference; RI: relative improvement.
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one hand, Steele et al. showed that 57% of patients electing 
continued medical therapy failed to improve 1 MCID with 
a mean relative score improvement of 16%. Moreover, 1 
in 5 patients experienced deterioration by  >  1  MCID  23. 
On the other hand, although surgical benefits are much 
more remarkable 1,8,9,24, the decision to face surgical cannot 
disregard evaluation of related risks and costs. To date, 
a tool that is able to identify patients who might benefit 
from surgery and the expected degree of improvement is 
still lacking. This is a natural consequence for not having a 
standardised staging system that drives treatment choices.
Many reports have investigated a number of factors that 
might influence the outcomes of CRS surgery. These 
include both patient-related factors (baseline SNOT-22, 
radiological extent of disease, presence of polyps, asthma 
or other comorbidities, gender, previous surgery) and 
surgical factors (experience of surgeon, timing of surgery, 
postoperative management)  25. It seems from previous 
regression studies, and partly confirmed by our work, 
that baseline SNOT-22 is one of major factors affecting 
outcomes  10. In this sense, the advantage of submitting 
CRS patients to SNOT-22 prior to any surgical treatment 
could, in theory, help physicians to inform them about their 
probable outcomes after ESS. For simplicity, explaining to 
a patient that he/she is likely to receive a 50% reduction 
in symptom load will aid informed consent and optimise 
preference-based decisions.
The fact is that, luckily, the majority of patients experience 
an improvement in symptoms after ESS, intended 
as a reduction of the SNOT-22 score after treatment 
(p  =  0.001)  1,8,9,24. We have shown that improvement of 
symptoms occurs in all groups and that the improvement is 
Table III. Probability of patients with CRSwNP achieving MCID after ESS 
based on preoperative SNOT-22 score group.
Preop. 
SNOT-22
Postop. 
SNOT-22
Probability 
of achieving 
MCID (%)
RI 
(%)
Group 1 
(10-19) 
n = 14
16.9 ± 2.1 7.7 ± 4.5 42.9%
(n = 6)
- 54.7%
Group 2 
(20-29)
n = 33
25.6 ± 2.7 16.9 ± 15.1 54.6%
(n = 18)
-33.7%
Group 3 
(30-39) 
n = 36
33.1 ± 2.5 17.1 ± 9.1 77.8%
(n = 28)
- 48.1%
Group 4 
(40-49) 
n = 36
44.5 ± 3.3 23.8 ± 18.1 88.9%
(n = 32)
- 46.8%
Group 5 
(50-59) 
n = 30
54.3 ± 2.7 27.4 ± 18.2 80%
(n = 24)
- 48.9%
Group 6 
(60-69) 
n = 26
64.3 ± 3.4 21.4 ± 19.2 92.3%
(n = 24)
- 66.6%
Group 7 
(70-79) 
n = 26
74 ± 2.9 36.6 ± 26.1 76.9%
(n = 20)
- 50.1%
Group 7 
(80-89) 
n = 12
81.5 ± 2.1 23.2 ± 16.2 100%
(n = 12)
- 71.6%
Group 9 
(90-99) 
n = 6
92 ± 3.8 39.7 ± 18.1 100%
(n = 6)
- 56.8%
Group 10
(100-110) 
n = 6
104 ± 2.2 26.7 ± 14.5 100%
(n = 6)
- 74.3%
Total 
n = 225
48.9 ± 20.7 22.9 ± 18.4 78.2%
(n = 176)
- 50.9%
MCID: minimal clinical important difference; RI: relative improvement.
Table IV. Probability of patients with CRSsNP achieving MCID after ESS 
based on preoperative SNOT-22 score group.
Preop. 
SNOT-22
Postop. 
SNOT-22
Probability 
of achieving 
MCID (%)
RI
(%)
Group 1 
(10-19) 
n = 10
14.8 ± 2.1 10.0 ± 1.9 25.0%
(n = 2)
- 30.6%
Group 2 
(20-29)
n = 27
23.9 ± 2.7 15.4 ± 7.6 55.6%
(n = 15)
- 33.8%
Group 3 
(30-39) 
n = 32
35.1 ± 2.9 18.0 ± 17.5 87.5%
(n = 28)
- 50%
Group 4 
(40-49) 
n = 50
44.4 ± 3.1 22.2 ± 15.9 84.0%
(n = 42)
- 50.3%
Group 5 
(50-59) 
n = 26
54.2 ± 2.2 24.1 ± 12.7 92.3%
(n = 24)
- 55.6%
Group 6 
(60-69) 
n = 25
66.4 ± 2.5 24.9 ± 19.5 92.0%
(n = 23)
- 62.5%
Group 7 
(70-79) 
n = 18
73.8 ± 3.5 34.0 ± 14.9 100%
(n = 18)
- 53.8%
Group 7 
(80-89) 
n = 6
83 ± 3.1 52.0 ± 17.6 100%
(n = 6)
- 37.4%
Group 9 
(90-99) 
n = 4
98.5 ± 0.6 50.0 ± 27.7 100%
(n = 4)
- 49.4%
Group 10 
(100-110) 
n = 0
/ / / /
Total 
n = 198
47.6 ± 19.3 23.1 ± 17.3 82.8%
(n = 162)
- 49.2%
MCID: minimal clinical important difference; RI: relative improvement.
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directly proportional to the baseline SNOT-22 value. In other 
words, patients with worse preoperative symptomatology 
obtain the greatest range of score reduction after treatment. 
However, this statistical significance might not imply a 
clinical benefit. Indeed, the MCID has been proposed 
to combat this conceptual vice by defining a threshold 
value by which a statistically significant result may also 
offer a clinically meaningful result. The MCID is the 
lowest degree of change that a patient will notice, which 
for SNOT-22 score has previously been defined as 8.9 
points in a 3-month postoperative score 18. However, what 
represents a clinically important change may vary from 
one individual to another and may not necessarily reflect 
the patients’ expectation for improvement after treatment. 
As an example, a patient reaching a MCID of 9 points in 
the postoperative SNOT-22 may not be satisfied with this 
outcome due to a persistent measurable burden of disease, 
despite achieving a noticeable improvement. To overcome 
the intrinsic limitations of MCID, a clinically significant 
change should be also outlined by a parameter expressing 
the true magnitude of postoperative improvement, i.e. the 
percentage of RI. Hence, integrating these measurements 
might optimise patient understanding and counselling. 
Rudmik et al. demonstrated that 80% of patients with 
a SNOT-22 score  >  30 improved by an average of 48% 
following ESS  20. Similarly, in our series, patients with 
SNOT-22 score >30 showed a 91.6% chance of achieving 
MCID with a mean 56.8% of RI. Also, a larger UK cohort 
showed a 66% chance of achieving a MCID with baseline 
SNOT-22 score > 30  26. On the other hand, patients with 
SNOT-22  <  30 have less than half the probability of 
achieving the MCID and a reduced degree of RI. That was 
evident in all the above-mentioned studies and confirmed in 
our series (44.2% mean MCID achievement, 38.9% mean 
RI). Therefore, although the baseline SNOT-22 score and 
chance of achieving the MCID is not intended to be used as 
an absolute threshold for eligibility for surgery, these global 
results suggest that a patient with low preoperative score 
might be less likely to benefit from surgery and caution 
should be paid when operating on patients with a score < 10. 
It is also true that only the categories of patients with lower 
baseline SNOT-22 values are likely to achieve a normal 
or near-normal status. Indeed, prior studies submitting 
SNOT-22 to patients with no sinus disease resulted in an 
average score of around 10 16,18; conversely, patients with 
higher baseline SNOT-22 values, despite a good RI, are still 
left with a significant burden of disease and remain more 
symptomatic than healthy controls. To be honest, SNOT-22 
groups on either extreme of the scoring scale contained 
small sample size in all studies, which makes it difficult 
to provide accurate statistical results and introduce larger 
degrees of uncertainty around the means of these groups. 
Therefore, larger collaborative CRS databases should be 
developed to better define these categories of patients 26,27 
and understand their behaviour.
Although our results are in line with the current literature, 
they should be interpreted with caution. First, though few 
in number, CRS patients with baseline SNOT-22 score < 10 
were excluded from the analysis because of their near-
normal status. Moreover, since all surgical procedures 
have been performed in the Day Surgery division, patients 
with severe comorbid asthma are not included in the study 
population. This choice obviously affected the overall 
mean values of percentage of MCID achievement and 
RI. Second, all surgeries were performed by specialist 
rhinologists, minimising the unfavourable outcomes due 
to surgical inexperience. Third, CRS is a dynamic disease 
characterised by fluctuating trends from quiescence to 
outbreaks. A one-off administration of a self-assessed 
questionnaire might not be enough reliable to assess the 
overall burden of the disease, especially considering a 
limited follow-up of 12 months. 
In light of the above, two reflections arise. If we assume 
that a patient with a low baseline SNOT-22 score has a 
low probability of reaching the MCID and that a patient 
with a high baseline SNOT-22 score has a high probability 
of reaching the MCID, but not enough RI to become 
asymptomatic, either we are far from having an ideal 
treatment for CRS or SNOT-22 (in general QoL-based 
questionnaires) may not be a sufficiently effective tool to 
evaluate treatment outcomes. While, on the one hand, basic 
research efforts are aimed at discovering innovative targeted 
therapies 28, on the other, clinical practice efforts are focused 
on defining new comprehensive method of outcomes 
evaluation. In particular, the attempt is to incorporate 
subjective and objective parameters since symptom-based 
items are influenced by psychological habitus and show 
a wide inter-individual variability. Indeed, our data show 
that in groups with low baseline SNOT-22 almost all of the 
SNOT-22 score is given by rhinologic symptoms, while 
in groups with high baseline SNOT-22 score rhinologic 
symptoms account only for about 50% of the global 
SNOT-22 value, suggesting that psychological and social-
functioning aspects significantly affect the SNOT-22 score. 
Furthermore, Hopkins et al. 18 demonstrated that when 
the sleep-psychological domain items dominate the total 
SNOT-22 score, ESS outcomes may be suboptimal. In 
fact, CRS patients that showed a moderately-severe total 
SNOT-22 score with high burden from sleep-psychosocial 
items may have less durable benefit after treatment, showing 
a statistically and clinically improvement at 3 months after 
ESS, followed by a worsening of symptoms at 6 months. 
S. Gallo et al.
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For this reason, these patients may be counselled to expect 
less benefit than those in whom nasal subdomain scores 
predominate 29. 
In this context, Hopkins et al. obtained a long list of potential 
parameters revising the current literature. After intricate 
statistical analysis, the 54 initial items were distilled down 
to a final core set of 15 items, over 4 domains, including the 
SNOT-22 repeated over time with some additional questions 
and the Lund-Kennedy score  30. This core outcome set 
(COS) represents the first “prototype” of an evaluation tool 
for CRS that is able to integrate subjective and objective 
parameters, but further work is still necessary to make it 
relevant for clinical practice. In this regard, a recent study 
highlighted a close correlation between symptoms and 
burden of inflammation. A cohort of CRSsNP patients 
undergoing ESS was clustered in 4 preoperative SNOT-
22-based groups. These groups were significantly different 
with respect to primary versus revision ESS status, number 
of previous sinonasal surgeries, asthma prevalence and 
total SNOT-22 scores. More interestingly, the cluster of 
subjects with the highest total preoperative SNOT-22 
score had the highest tissue eosinophilia compared to the 
other symptomatic groups and a more frequent diagnosis 
of asthma, suggesting that a high burden of inflammation 
correlates with worse symptomatology 29. 
Conclusions
Submitting CRS patients to SNOT-22 prior to surgical 
treatments might help to inform about their probable 
outcomes, although it is strongly influenced by individual 
perception. Based on recent preliminary observations, the 
integration of SNOT-22 scores and tissue histopathology 
could represent an innovative method to predict treatment 
outcomes in CRS patients. Further studies are needed to define 
a simple and effective evaluation tool by implementing the 
knowledge of pathophysiological mechanisms underlying 
the different expressions of this disease. Eventually, this 
will lead to identify new histopathological-biomolecular 
pathways that are able to classify the CRS patients into 
homogeneous subgroups, to establish endotype-driven 
treatments and possibly provide objective predictors of 
response to therapy.
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